The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.25
Bid: 9.70
Ask: 10.70
Change: 0.00 (0.00%)
Spread: 1.00 (10.309%)
Open: 10.20
High: 10.20
Low: 10.20
Prev. Close: 10.20
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Scancell raises GBP12 million in total from fundraise

Tue, 19th Dec 2023 13:35

(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of shares.

Scancell is an Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease

On Tuesday, it has raised GBP1.2 million through an open offer of 11.1 million shares.

The open offer shares were priced at 11 pence each. Shares in Scancell were up 2.3% to 11.00p each on Tuesday afternoon.

Earlier in December, Scancell said it had raised GBP10.7 million from the placing and subscription of 97.0 million new shares at 11p each. At the time, it announced an open offer, to raise up to a further GBP2.0 million.

"The funds raised today will further drive the company's progress with its lead programmes, including SCIB1, which recently demonstrated an unprecedented objective response rate of 85% in patients with unresectable melanoma in initial data from the Scope study, and Modi-1 through its next clinical steps," said Chief Executive Officer Lindy Durrant at the start of December.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
18 Sep 2015 09:23

Bigger loss but positive drug trial results for Scancell Holdings

(ShareCast News) - Scancell Holdings's losses increased marginally in the year ended 30 April 2015. The cancer immunotherapy developer announced on Friday a wider loss of £2.414m from £2.222m last year. It comes as a result of expected additional expenditure on its SCIB1 ImmunoBody clinical trials

Read more
18 Sep 2015 07:49

Scancell Holdings Loss Wider On Higher Development Costs

Read more
30 Jul 2015 09:40

Scancell Signs Research Collaboration Deal With ImmunID

Read more
9 Jul 2015 08:57

Scancell Closes Patient Recruitment For Next Phase Of SCIB1 Trials

Read more
2 Jun 2015 12:19

Scancell gives positive update on melanoma treatment data

Biopharmaceutical company Scancell Holdings reported further encouraging results from the ongoing 'Phase 1/2' clinical trial of its melanoma treatment SCIB1, which it presented at the annual meeting of the American Society of Clinical Oncology in Chicago. The data showed that all 16 patients with re

Read more
2 Jun 2015 07:27

Scancell Reports Encouraging Ongoing SCIB1Trial Results

Read more
24 Mar 2015 10:21

Scancell Says New Data Supports SCIB2 Combination Treatment

Read more
12 Jan 2015 09:47

Scancell Sees Positive Data In On-Going Phase I/2 SCIB1Trial

Read more
14 Oct 2014 11:23

UK MIDDAY BRIEFING: Life's No Catwalk For Luxury Goods Makers

Read more
14 Oct 2014 11:09

UK WINNERS & LOSERS: Miners Continue Run, Oil Companies Fall

Read more
14 Oct 2014 07:44

Scancell Shares Boosted By Positive SCIB-1 Trial Results

Read more
14 Oct 2014 07:32

UK MORNING BRIEFING: Burberry And Hargreaves Lansdown Lead Declines

Read more
14 Oct 2014 05:22

UK AGM, EGM Calendar - Week Ahead

Read more
13 Oct 2014 14:57

UK AGM, EGM Calendar - Week Ahead

Read more
13 Oct 2014 05:30

UK AGM, EGM Calendar - Week Ahead

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.